Investigation of TAp63 gene expression and follicle count using melatonin in cisplatin-induced ovarian toxicity


  • Hacı Öztürk Şahin Department of Obstetrics and Gynecology, University of Çanakkale Onsekiz Mart, Çanakkale, Turkey
  • Mehmet Nuri Duran Department of Obstetrics and Gynecology, University of Çanakkale Onsekiz Mart, Çanakkale, Turkey
  • Fatma Sılan Department of Medical Genetics, University of Çanakkale Onsekiz Mart, Çanakkale, Turkey
  • Ece Sılan Department of Molecular Biology and Genetics, University of Çanakkale Onsekiz Mart, Çanakkale, Turkey
  • Duygu Sıddıkoglu Department of Biostatistics, University of Çanakkale Onsekiz Mart, Çanakkale, Turkey
  • Nihal Kılınç Department of Pathology, University of Çanakkale Onsekiz Mart, Çanakkale, Turkey



Cisplatin, Melatonin, TAp63, Primordial follicle, Ovarian reserve


Background: Premature ovarian failure is among the most important side effects of chemotherapy during reproductive period. Preserving ovarian function is gradually gaining importance during oncologic treatment. The present study aims to investigate the potential of melatonin to protect from cisplatin-induced ovarian toxicity in rats.

Methods: Twenty-nine female rats were divided to three groups: Saline control group (group 1), cisplatin group (group 2), and cisplatin and melatonin group (group 3). While the rats in groups 2 and 3 were administered 5 mg/kg single dose of cisplatin via intra-peritoneal (IP) route, the rats in group 3 were started on melatonin (20 mg/kg IP) before cisplatin administration and continued during 3 consecutive days. Ovaries were removed one week after cisplatin administration in all groups. Blood samples were obtained before the rats were decapitated. Histological evaluation, follicle count, and classification were performed. TAp63 mRNA expression was evaluated using mRNA extraction and real-time polymerase chain reaction (PCR) method. Serum estradiol (E2) and anti-Mullerian hormone (AMH) values were measured with enzyme immune-assay technology.

Results: While primordial follicles were seen to decrease in group 2 as compared to group 1 (p=0.023), primordial follicle count was observed to be preserved significantly in melatonin group as compared to group 2 (p=0.047). Moreover, cisplatin-induced histo-pathological morphology was preserved in favor of normal histology in melatonin group. A significant difference was not observed between groups with regard to mean serum AMH and E2 values (p=0.102 and p=0.411, respectively). While TAp63 gene expression significantly increased in group 2 as compared to control group (p=0.001), we did not detect a statistically significant difference in cisplatin and melatonin group, although gene expression decreased (p=0.34).

Conclusions: We conclude that concurrent administration of melatonin and cisplatin may protect from ovarian damage.

Author Biography

Hacı Öztürk Şahin, Department of Obstetrics and Gynecology, University of Çanakkale Onsekiz Mart, Çanakkale, Turkey

Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynecological Oncology


Waxman J. Chemotherapy and the adult gonad: a review. J R Soc Med. 1983;76(2):144-8.

Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500-10.

Jensen AK, Kristensen SG, Macklon KT, Jeppesen JV, Fedder J, Ernst E et al. Outcomes of transplantations of cryopreserved ovarian tissue to 41 women in Denmark. Hum Reprod. 2015;30(12):2838-45.

Donfack NJ, Alves KA, Araújo VR, Cordova A, Figueiredo JR, Smitz J et al. Expectations and limitations of ovarian tissue transplantation. Zygote. 2017;25(4):391-403.

Laurell G, Beskow C, Frankendal B, Borg E. Cisplatin administration to gynecologic cancer patients. Long-term effects on hearing. Cancer. 1996;78(8):1798-804.

Suh EK, Yang A, Kettenbach A, Bamberger C, Michaelis AH, Zhu Z et al. p63 protects the female germ line during meiotic arrest. Nature. 2006;444(7119):624-8.

Livera G, Petre-Lazar B, Guerquin MJ, Trautmann E, Coffigny H, Habert R. p63 null mutation protects mouse oocytes from radio-induced apoptosis. Reproduction. 2008;135(1):3-12.

Gonfloni S, Di Tella L, Caldarola S, Cannata SM, Klinger FG, Di Bartolomeo C, et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med. 2009;15(10):1179-85.

Peters H, Levy E. Effect of irradiation in infancy on the mouse ovary; a quantitative study of oocyte sensitivity. J Reprod Fertil. 1964;7:37-45.

Kalich-Philosoph L, Roness H, Carmely A, Fishel-Bartal M, Ligumsky H, Paglin S et al. Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility. Sci Transl Med. 2013;5(185):185-62.

Satoh M, Kashihara N, Fujimoto S, Horike H, Tokura T, Namikoshi T et al. A novel free radical scavenger, edarabone, protects against cisplatin-induced acute renal damage in vitro and in vivo. J Pharmacol Exp Ther. 2003;305(3):1183-90.

Barberino RS, Menezes VG, Ribeiro AEAS, Palheta Jr RC, Jiang X, Smitz JE et al. Melatonin protects against cisplatin-induced ovarian damage in mice via the MT1 receptor and antioxidant activity. Biol Reprod. 2017;96(6):1244-55.

Nazıroǧlu M, Karaoğlu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology. 2004;195(2-3):221-30.

Reiter RJ, Tan DX, Tamura H, Cruz MH, Fuentes-Broto L. Clinical relevance of melatonin in ovarian and placental physiology: a review. Gynecol Endocrinol. 2014;30(2):83-9.

Galano A, Medina ME, Tan DX, Reiter RJ. Melatonin and its metabolites as copper chelating agents and their role in inhibiting oxidative stress: a physicochemical analysis. J Pineal Res. 2015;58(1):107-16.

Venegas C, García JA, Escames G, Ortiz F, López A, Doerrier C et al. Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res. 2012;52(2):217-27.

Tamura H, Takasaki A, Taketani T, Tanabe M, Kizuka F, Lee L et al. The role of melatonin as an antioxidant in the follicle. J Ovarian Res. 2012;5:5.

Miller SC, Pandi-Perumal SR, Esquifino AI, Cardinali DP, Maestroni GJ. The role of melatonin in immuno-enhancement: potential application in cancer. Int J Exp Pathol. 2006;87(2):81-7.

Mediavilla MD, Cos S, Sánchez-Barceló EJ. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci. 1999;65(4):415-20.

Hara M, Yoshida M, Nishijima H, Yokosuka M, Iigo M, Ohtani-Kaneko R, et al. Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats. J Pineal Res. 2001;30(3):129-38.

Pedersen T, Peters H. Proposal for a classification of oocytes and follicles in the mouse ovary. J Reprod Fertil. 1968;17(3):555-7.

Kelsey TW, Anderson RA, Wright P, Nelson SM, Wallace WH. Data-driven assessment of the human ovarian reserve. Mol Hum Reprod. 2012;18(2):79-87.

Visser JA, Themmen AP. Anti-Müllerian hormone and folliculogenesis. Mol Cell Endocrinol. 2005;234(1-2):81-6.

Yeh J, Kim B, Liang YJ, Peresie J. Müllerian inhibiting substance as a novel biomarker of cisplatin-induced ovarian damage. Biochem Biophys Res Commun. 2006;348(2):337-44.

Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C, Dewailly D. Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online. 2010;20(2):280-5.

Li X, Yang S, Lv X, Sun H, Weng J, Liang Y, et al. The mechanism of mesna in protection from cisplatin-induced ovarian damage in female rats. J Gynecol Oncol. 2013;24(2):177-85.

Yücebilgin MS, Terek MC, Ozsaran A, Akercan F, Zekioglu O, Isik E et al. Effect of chemotherapy on primordial follicular reserve of rat: an animal model of premature ovarian failure and infertility. Aust N Z J Obstet Gynaecol. 2004;44(1):6-9.

Borovskaya TG, Goldberg VE, Fomina TI, Pakhomova AV, Kseneva SI, Poluektova ME et al. Morphological and functional state of rat ovaries in early and late periods after administration of platinum cytostatics. Bull Exp Biol Med. 2004;137(4):331-5.

Abir R, Ben-Haroush A, Felz C, Okon E, Raanani H, Orvieto R et al. Selection of patients before and after anticancer treatment for ovarian cryopreservation. Hum Reprod. 2008;23(4):869-77.

Taşkın MI, Yay A, Adali E, Balcioglu E, Inceboz U. Protective effects of sildenafil citrate administration on cisplatin-induced ovarian damage in rats. Gynecol Endocrinol. 2015;31(4):272-7.

Maiani E, Di Bartolomeo C, Klinger FG, Cannata SM, Bernardini S, Chateauvieux S et al. Reply to: Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib. Nat Med. 2012;18(8):1172-4.

Majidinia M, Sadeghpour A, Mehrzadi S, Reiter RJ, Khatami N, Yousefi B. Melatonin: A pleiotropic molecule that modulates DNA damage response and repair pathways. J Pineal Res. 2017;63(1):e12416.

Proietti S, Cucina A, Dobrowolny G, D'Anselmi F, Dinicola S, Masiello MG, et al. Melatonin down-regulates MDM2 gene expression and enhances p53 acetylation in MCF-7 cells. J Pineal Res. 2014;57(1):120-9.

Santoro R, Mori F, Marani M, Grasso G, Cambria MA, Blandino G et al. Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation. Carcinogenesis. 2013;34(5):1051-61.

Jang H, Na Y, Hong K, Lee S, Moon S, Cho M et al. Synergistic effect of melatonin and ghrelin in preventing cisplatin-induced ovarian damage via regulation of FOXO3a phosphorylation and binding to the p27Kip1 promoter in primordial follicles. J Pineal Res. 2017;63(3):e12432.

Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem. 2007;7(1):3-18.

Galano A, Tan DX, Reiter RJ. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J Pineal Res. 2013;54(3):245-57.

Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine. 2005;27(2):119-30.

Tan DX, Reiter RJ, Manchester LC, Yan MT, El-Sawi M, Sainz RM, et al. Chemical and physical properties and potential mechanisms: melatonin as a broad-spectrum antioxidant and free radical scavenger. Curr Top Med Chem. 2002;2(2):181-97.

Kim MK, Park EA, Kim HJ, Choi WY, Cho JH, Lee WS et al. Does supplementation of in-vitro culture medium with melatonin improve IVF outcome in PCOS? Reprod Biomed Online. 2013;26(1):22–9.

Ateşşahin A, Sahna E, Türk G, Çeribaşi AO, Yılmaz S, Yüce A, et al. Chemoprotective effect of melatonin against cisplatin-induced testicular toxicity in rats. J Pineal Res. 2006;41(1):21-7.

Yeh J, Kim BS, Peresie J. Protection against cisplatin-induced ovarian damage by the antioxidant sodium 2-mercaptoethanesulfonate (mesna) in female rats. Am J Obstet Gynecol. 2008;198(4):463,e1-6.

Altuner D, Gulaboglu M, Yapca OE, Cetin N. The effect of mirtazapine on cisplatin-induced oxidative damage and infertility in rat ovaries. Scientific World J. 2013;2013:327240.

Melekoglu R, Ciftci O, Eraslan S, Cetin A, Basak N. Beneficial effects of curcumin and capsaicin on cyclophosphamide-induced premature ovarian failure in a rat model. J Ovarian Res. 2018;11(1):33.




How to Cite

Şahin, H. Öztürk, Duran, M. N., Sılan, F., Sılan, E., Sıddıkoglu, D., & Kılınç, N. (2021). Investigation of TAp63 gene expression and follicle count using melatonin in cisplatin-induced ovarian toxicity. International Journal of Research in Medical Sciences, 9(3), 658–664.



Original Research Articles